降纤酶治疗急性脑梗死双盲对照研究

目的 观察降纤酶治疗急性脑梗死的临床疗效。方法 用国产双盲编号的降纤酶静滴治疗发病２４ｈ内的急性脑梗死患者６５例（治疗组３１例、对照组３４例）,并同时于治疗前、后进行神经功能缺损评分及检测血浆纤维蛋白原（ＦＧ）、凝血酶原时间（ＰＴ）、凝血酶原活动度（ＰＡ）。结果 神经功能缺损评分显著进步率,降纤酶治疗组７４．２％,明显优于对照组２９．２％,两组比较有显著性差异（Ｐ〈０．０１）;治疗组ＦＧ降低明显优     

降纤酶治疗急性脑梗死临床对照观察

目的 验证降纤酶治疗急性脑梗死的临床疗效及其血液学的改变。方法 采用病历与对照的方法将病例随机分为两组。降纤酶组１４２例（治疗组）,低分子右旋糖酐组４０例（对照组）,治疗前两组纤维蛋白原和神经功能缺损程度评分无差异（Ｐ〉０．０５）。结果 治疗后３天神经功能损程度评分两组比较有差异（Ｐ〈０．０５）,治疗后１４天两组有显著性差异（Ｐ〈０．００１）,降纤酶治疗急性脑梗死的总有效率比较有差异（Ｐ〈０．０５     

降纤酶治疗急性缺血性脑血管病的疗效观察

目的 观察应用降纤酶治疗急性缺血性脑血管病的疗效。方法 将急性缺血性服血管病患者105例,随机分为治疗组和对照组。治疗线54例,用降纤酶10u（体重在60kg以下得5u）加生理盐水250ml静脉滴注,每天1次,连用3天,第4天后改为隔日静滴1次,降纤酶总量达到60u;对照组51例,用复方丹参20ml加0．9％生理盐水250ml静脉滴汪,每天1次,连用14天为1个疗程。于治疗后第7天、第14天检测两组治疗前后的神经功能缺损评分和日常生活能力评分,以评价其临床疗效。于治疗后第7天、第14天检测两组治疗前后的神经功能缺损评分和日常生活能力评分,以评价其临床疗效。结果 治疗组的有效率和显效率分别达到87．03％和62．9％,而对照组的有效率和显效率分别为60．78％和37．25％,两组比较有显著性差异（P＜05）。两组治疗后的日常生活能力和神经功能缺损评分均有显著性差异（P＜0．01）,血液流变学指标有明显的改善（P＜0．01）。结论 降纤酶具有降低血浆纤维蛋白原、改善微循环、降低全血粘度等作用,是治疗急性缺血性脑血管病安全、有效的药物。     

降纤酶治疗急性脑梗死血浆D—二聚体的研究

目的 探讨降纤酶治疗急性脑梗死患者血浆－Ｄ二聚体水平的变化以证实其溶栓作用。方法 采用前瞻性、随机、双盲对照方法。将７０例急性脑梗死病人分为治疗组和对照组。分别治疗前和治疗后第６天测血浆纤维蛋白原的Ｄ－二聚体。结果 治疗组血浆纤维蛋白原治疗后比前有明显下降,两者比较有明显的差异（Ｐ〈０．０１）。血浆Ｄ－二聚体治疗后比治疗前有明显的增高,两者比较有明显的差异（Ｐ〈０．０１）。而对照组均无明显差异（Ｐ     

降纤酶治疗急性脑梗死Ⅱ期临床研究

目的探讨降纤酶治疗急性脑梗死的有效性和安全性,并进行客观评价.方法按照全国脑防办<降纤酶治疗急性脑梗死第二阶段临床再评价研究>实施方案,采用前瞻性、随机、双盲、安慰剂对照的临床研究方法,将49例符合标准的急性脑梗死患者随机分为降纤酶组和对照组.评定指标包括脑卒中的临床神经功能缺损程度评分、Barthel指数、血浆纤维蛋白原水平、副作用.结果治疗组23例,终止治疗5例,其中1例自动退出试验、2例消化道出血、1例出现皮肤大片淤斑、1例突然死亡;对照组26例,终止1例,为自动退出试验.(1)治疗组应用降纤酶后血浆纤维蛋白原水平降低与对照组比较,差异非常显著(P＜0.001).尤其用药第6天最显著;(2)治疗后14天临床神经功能缺损评分减少优于对照组,有显著性差异(P＜0.05),但第14天、3个月时Barthel指数评分并无显著差异;(3)治疗组应用降纤酶后有1例病情加重,而对照组中有4例病情加重;(4)治疗组中有2例出现上消化道出血,1例皮肤大片淤斑,而对照组无上述情况.结论降纤酶降低血浆纤维蛋白原的作用确切,对减少神经功能缺损评分疗效显著,具有抑制急性脑梗死病情进展的作用,本组无1例并发颅内出血,但有消化道出血及皮下出血,有增加出血危险性的可能.     

He—Ne激光治疗带状疱疹神经痛

４３例带状疱疹病人随机分为Ｈｅ－Ｎｅ激光治疗组（２９例）及红外线对照组（１４例）,分别进行局部治疗（两组全身用药相同）。采用“６点行为疼痛测定法”对治疗期及治疗完成时的神经痛程度客观评分,经方差分析,治疗期及治疗后的结果显示激光治疗组的疗效明显优于对照组（ｐ＜０．０５～０．０１）;３月后随访,疱疹后神经痛的发生率两组相比亦有显著性差异（ｐ＜０．０１）。并对Ｈｅ－Ｎｅ激光在治疗带状疱疹神经痛的作用机理进行了讨论。     

头颅局部亚低温对脑梗死治疗作用的临床研究

目的：观察头颅局部行亚低温治疗脑梗死后患者血清一氧化氮、内皮素以及细胞间粘附分子含量的变化,探讨亚低温治疗对脑组织发挥保护作用的机制。方法：搜集2012年5月至2013年2间,哈尔滨医科大学附属第四医院神经内科收治的62例脑梗死患者,并随机分为亚低温治疗组（32例）和常规治疗对照组（30例）,治疗组在药物治疗脑梗死的同时加用局部亚低温治疗技术,在治疗前、治疗后3、7、14d进行一氧化氮、内皮素及细胞间粘附分子的测定;两组患者分别于治疗前以及治疗后第30d,对神经功能缺损采用NIHSS量表进行评分,对日常生活活动能力采用Bathel指数评分,对运动功能采用FuglMeyer法进行评价。结果：在治疗后第3、7、14天,亚低温治疗组一氧化氮含量较对照组显著升高（均为P〈0．01）,在治疗后第7天亚低温治疗组内皮素含量低于对照组（P〈0．05）,第3、14天亚低温组内皮素含量显著低于对照组（P〈0．01）;治疗前两组NIHSS评分、Bamel指数和FuglMeyer评分差异均无显著性意义（P〉0．05）。在治疗组治疗后的第3、7、14天,亚低温治疗组细胞间粘附分子与治疗前相比,均出现降低（P〈0．05）;而且在第3天,治疗组和对照组有显著性差异（P〈0．05）。治疗1个月后,亚低温治疗组NIHss评分比常规治疗组显著降低,亚低温治疗组Bathel指数和FuglMeyer评分均明显高于对照组,差异具有显著性。结论：局部亚低温治疗对血管内皮细胞功能有较好的保护作用,可改善脑梗死患者神经功能缺损及预后。     

龙津降纤酶治疗急性缺血性卒中临床疗效观察

目的 观察龙津降纤酶对急性缺血性情卒中的治疗效果。方法 选择诊断明确的急性因性卒中病人８０例,随机分为２组,对照组４０例,５％葡萄糖液５００ｍｌ加血塞通小射液０．４ｇ静脉滴注,连用１４天,降纤酶组４０例,入院后第１～３天分别给降酶１０ｕ加入生理盐水１００ｍｌ,静脉主１ｈ以上,按临床神经功能缺失程度评分标准于治疗前及治疗在进行疗效评定。结果 降纤酶组总有效率达９２．５％,显效率为７２．５％,明显优于     

降纤酶对急性脑梗死患者凝血指标的影响

目的 对４０例急性脑梗死患者应用降纤酶治疗,监测治疗前后凝血指标变化。方法 采用美国库尔特公司２００型血凝仪检测凝血指标。结果 降纤酶可以显著降低纤维蛋白原（Ｐ〈０．０５）,对其它凝血指标有影响,但无统计学意义（Ｐ〉０．０５）。结论 降低纤维蛋白原是降纤酶的显著特征。     

纳络酮治疗急性酒精中毒24例

３６例急性酒精中毒病人．随机分成治疗组和对照组,分别为２４、１２例。对照组按常规治疗,治疗组在常规治疗的基础上加用纳络酮静注或静滴,结果治疗组病人苏醒和出院时间均比对照组提前。经统计学处理,两组苏醒时间差异具有非常显著性（Ｐ＜０．００１）,出院时间差异具有显著性（Ｐ＜０．０５）,提示纳络酮明显优于常规治疗。因此作者建议对急性重度酒精中毒病人应常规应用纳络酮。文中对纳络酮的作用机理进行了讨论。     

Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis

It has now been over twenty years since a novel herpesviral genome was identified in Kaposi's sarcoma biopsies. Since then, the cumulative research effort by molecular biologists, virologists, clinicians, and epidemiologists alike has led to the extensive characterization of this tumor virus, Kaposi's sarcoma-associated herpesvirus(KSHV; also known as human herpesvirus 8(HHV-8)), and its associated diseases. Here we review the current knowledge of KSHV biology and pathogenesis, with a particular emphasis on new and exciting advances in the field of epigenetics. We also discuss the development and practicality of various cell culture and animal model systems to study KSHV replication and pathogenesis.     

A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility

正Dear Editor,In December 2019, a novel human coronavirus caused an epidemic of severe pneumonia(Coronavirus Disease 2019,COVID-19) in Wuhan, Hubei, China(Wu et al. 2020; Zhu et al. 2020). So far, this virus has spread to all areas of China and even to other countries. The epidemic has caused 67,102 confirmed infections with 1526 fatal cases     

Curcuminoids as inhibitors of thioredoxin reductase: A receptor based pharmacophore study with distance mapping of the active site

Curcumin is the yellow pigment of turmeric that interacts irreversibly forming an adduct with thioredoxin reductase (TrxR), an enzyme responsible for redox control of cell and defence against oxidative stress. Docking at both the active sites of TrxR was performed to compare the potency of three naturally occurring curcuminoids, namely curcumin, demethoxy curcumin and bis-demethoxy curcumin. Results show that active sites of TrxR occur at the junction of E and F chains. Volume and area of both cavities is predicted. It has been concluded by distance mapping of the most active conformations that Se atom of catalytic residue SeCYS498, is at a distance of 3.56 from C13 of demethoxy curcumin at the E chain active site, whereas C13 carbon atom forms adduct with Se atom of SeCys 498. We report that at least one methoxy group in curcuminoids is necessary for interation with catalytic residues of thioredoxin. Pharmacophore of both active sites of the TrxR receptor for curcumin and demethoxy curcumin molecules has been drawn and proposed for design and synthesis of most probable potent antiproliferative synthetic drugs.     

The structure, reproduction and taxonomy of Vidalia and Osmundaria (Rhodophyta, Rhodomelaceae)

Comprises species occurring mostly in subtidal habitats in tropical, subtropical and warm-temperate areas of the world. An analysis of the type species, V. spiralis (Sonder) Lamouroux ex J. Agardh, a species from Australia, establishes basic characters for distinguishing species in the genus. These characters are (1) branching patterns of thalli, (2) flat blades that may be spiralled on their axis, (3) width of the blade, (4) primary or secondary derivation of sterile and fertile branchlets and (5) position of sterile and fertile branchlets on the thalli. Application of the latter two characters provides an important basic method for separation of species into three major groups. Osmundaria , a genus known only in southern Australia, was studied in relation to Vidalia , and its separation from the Vidalia assemblage is not accepted. Species of Vidalia therefore are transferred to the older genus name, Osmundaria. Two new species, Osmundaria papenfussii and Osmundaria oliveae are described from Natal. Confusion in the usage of the epithet, Vidalia fimbriala Brown ex Turner has been clarified, and Vidalia gregaria Falkenberg, described as an epiphyte on Osmundaria pro/ifera Lamouroux, is revealed to be young branches of the host, Osmundaria prolifera.     

New or rare chromosome counts in Artemisia L. (Asteraceae, Anthemideae) and related genera from Kazakhstan

Fifteen chromosome counts of six Artemisia taxa and one species of each of the genera Brachanthemum, Hippolytia, Kaschgaria, Lepidolopsis and Turaniphytum are reported from Kazakhstan. Three of them are new reports, two are not consistent with previous counts and the remainder are confirmations of very scarce (one to four) earlier records. All the populations studied have the same basic chromosome number, x = 9, with ploidy levels ranging from 2x to 6x. Some correlations between ploidy level, morphological characters and distribution are noted.